Translational Relevance
Immunotherapy is a promising treatment modality for cancer. However, predicting which patients will benefit remains a challenge. Fundamental to the outgrowth of malignant cells is their ability to evade immune elimination and therefore, understanding the mechanisms exploited by a cancer may help guide the application of immunotherapy. Here, we propose that the tailoring of immunotherapy to patients may require knowledge of tumor antigenicity and immunogenicity as well as the composition of the tumor microenvironment. In our discussion, we describe challenges and future directions in applying this knowledge to enhancing the efficacy of immunotherapy by improving patient selection and by informing the development of rational combination therapies.
Introduction
The immune system is a critical regulator of tumor biology with the capacity to support or inhibit tumor development, growth, invasion and metastasis. Strategies designed to harness the immune system are the focus of several recent promising therapeutic approaches for cancer patients. For example, adoptive T cell therapy has produced impressive remissions in patients with advanced malignancies (1) . In addition, therapeutic monoclonal antibodies designed to disrupt inhibitory signals received by T cells through the cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4; also known as CD152) and programmed cell death-1 (PD-1; also known as CD279) molecules are demonstrating long-term survival benefits for some patients with metastatic melanoma (2, 3) . However, not all tumors appear to respond to these immunomodulatory maneuvers. This observation emphasizes the heterogeneity of cancer and suggests the existence of additional immunoregulatory mechanisms in many patients. A major challenge for cancer immunotherapy, therefore, lies in understanding these resistance mechanisms for selecting patients who are most likely to benefit.
A central tenet of cancer immunotherapy is that the immune system actively surveys for malignant transformation and can be induced to recognize and eliminate malignant cells. This premise was initially proposed by Thomas and Burnet in 1957 in the immunosurveillance hypothesis which postulated a role for the immune system in controlling the development and outgrowth of nascent transformed cells (4., 5) . This hypothesis has since been refined based on knowledge that the immune system cannot only protect against tumor development but can also select for tumors with decreased antigenicity and/or immunogenicity and therefore, promote tumor outgrowth. In this process termed "cancer immunoediting", cancer clones evolve to avoid immune-mediated elimination by leukocytes that have anti-tumor properties (6) . However, some
Research. tumors may also escape elimination by recruiting immunosuppressive leukocytes which orchestrate a microenvironment that spoils the productivity of an anti-tumor immune response (7) . Thus, although the immune system can be harnessed, in some cases, for its anti-tumor potential, clinically relevant tumors appear to be marked by an immune system that actively selects for poorly immunogenic tumor clones and/or establishes a microenvironment that suppresses productive anti-tumor immunity (Figure 1 ).
Immune signatures for cancer immunotherapy are actively being explored across many clinical studies (8) . However, unlike small molecule inhibitors, for which the presence or absence of a target mutation may predict response, the efficacy of immunotherapy relies on the functional competence of multiple immunological elements. For example, strategies designed to harness the anti-tumor potential of endogenous T cells rely on the proper execution of a series of steps which have been described in the cancer immunity cycle (9) . In this cycle, tumor cells must release immunogenic tumor antigens for the priming and activation of tumor-specific T cells.
Tumor-reactive T cells must then infiltrate tumor tissue and recognize cancer cells in the context of a peptide-MHC complex to induce cancer cell death. To evade immune mediated elimination, tumors must then develop strategies that disrupt this cycle. Therefore, predicting the clinical benefit of T cell immunotherapy is likely to require an understanding of each of these steps as it relates to a patient's individual tumor. Here, we discuss tumor antigenicity, tumor immunogenicity and the tumor microenvironment as key elements of this cycle which may be used to predict clinical benefit with T cell immunotherapy and guide the development of rational combinations.
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The ability of the immune system to distinguish between normal and malignant cells is fundamental to cancer immunotherapy and relies, in part, on malignant cells retaining sufficient antigenicity. Tumors can express a variety of non-mutated and mutated antigens which have the potential to elicit tumor-specific immune responses (10). However, to avoid immune-mediated elimination, cancer cells may lose their antigenicity. Loss of antigenicity can arise due to the immune selection of cancer cells which lack or mutate immunogenic tumor antigens as well as through the acquisition of defects or deficiencies in antigen presentation (e.g. loss of major histocompatibility (MHC) expression or dysregulation of antigen processing machinery) (6) . As a result, knowledge of the antigenicity of malignant cells may inform the potential susceptibility of a cancer to immune elimination by endogenous T cells.
Tumor antigens can be derived from viral proteins, proteins encoded by cancer-germline genes, differentiation antigens and proteins arising from somatic mutations or gene rearrangements (10). However, because malignant cells across patients and even within the same patient can be quite different, it remains unclear how to effectively quantify the antigenicity of a cancer. One approach might be to determine the frequency of somatic mutations within a cancer as a predictor of neoantigens. Until recently though, it was unclear whether mutated proteins that produce "neoantigens" could even serve as effective targets for cancer immunotherapy. Recent studies have now demonstrated that T cells recognizing neoantigens infiltrate tumor tissue and can mediate strong tumor regressions after ex vivo expansion and adoptive transfer (11) (12) (13) . These findings raise the possibility that tumor mutational frequency might correlate with responsiveness to immunotherapy (14) .
Mutational analysis of solid tumor malignancies has recently revealed significant variability with some immunogenic cancers, such as melanoma, displaying a high mutation rate and other non-immunogenic cancers, such as PDAC, showing a low mutation rate (15, 16) .
While this finding has sometimes been used to explain the poor immunogenicity of cancers like PDAC, it is also important to note that some cancers, such as renal and bladder, despite being characterized by few somatic mutations have demonstrated significant responsiveness to immunotherapy (3) . Thus, at this time it remains unclear whether mutational status alone can be used to effectively identify patients with highly antigenic tumors. Certainly, not all neoantigens produced by mutations will necessarily be strongly immunogenic and non-mutated antigens may also represent key targets for cancer immunotherapy (10). colorectal cancer (21) and for predicting the efficacy of immunotherapy in bladder cancer (22) and chemotherapy in ovarian cancer (23). Together, we believe that this data strongly argues a role for MHC class I/II testing of tumor tissue as a measure of antigenicity in order to identify patients who are most likely to benefit from T cell immunotherapy. We are mindful, though, that there are likely to be challenges with this approach including the capacity of MHC expression to be enhanced in response to cytokines, such as interferons, which may be induced by T cell immunotherapy. In addition, tumor biopsies to assess for MHC expression are unlikely to account for the significant level of cancer cell heterogeneity that can been seen within tumors and even between tumor lesions within the same patient. Despite these potential drawbacks though, we propose that knowledge of the antigenicity of a patient's cancer informed through MHC testing may provide key insights into how to effectively personalize immunotherapy. tumor cells and surrounding stromal cells and/or the expression of negative regulatory markers present on tumor-infiltrating lymphocytes (e.g. PD-1, LAG-3, TIM-3, VISTA, CD244, CD160, and BTLA) (26, 27) . Similar to PD-1/PD-L1, these molecular pathways can act to fine-tune the cellular fate of tumor-infiltrating T cells. In fact, it is likely that some redundancy exists between these immunoinhibitory pathways and PD-1/PD-L1 such that individual or combinations of therapies that disrupt signaling through these alternative immunoregulatory pathways may also alter the balance between activation and inhibitory signals received by T cells and lead to productive anti-tumor T cell immunity (28) . The challenge, though, will be in understanding how to select patients for a particular immunomodulatory therapy as combination therapies may unveil increased toxicity (29) . As such, it may be necessary to administer therapies sequentially particularly since modulation of the immune microenvironment due to improved T cell function may induce alternative mechanisms of immune evasion (30) . This concept implies that the immunogenicity of cancer as suggested by the immunoediting theory is a dynamic process that is shaped by the phenotype of the surrounding microenvironment. (36) and suggests that combination therapy will be necessary in many cases to prevent the emergence of immune escape variants.
One example of treatment-induced immunoresistance seen in cancer involves the production of indoleamine 2,3-dioxygenase (IDO) within the tumor microenvironment in response to IFN- produced by anti-tumor T cells (30) . IDO is an enzyme that catalyzes the degradation of the essential amino acid tryptophan to kynurenine and in doing so, drives T cell suppression. The role of IDO as an immune resistance mechanism to immune checkpoint therapy (including anti-CTLA-4 and anti-PD-1 blocking antibodies) is supported by preclinical data (37) and is the basis for an ongoing clinical study investigating combination therapy with CTLA-4 blocking antibody ipilimumab and INCB024360, a selective inhibitor of IDO (NCT01604889).
We hypothesize that the conditional state of the tumor microenvironment is pliable and that an optimal state exists for enhanced responsiveness to T cell immunotherapy. The capacity of single agent immune checkpoint blockade with anti-CTLA-4 and anti-PD-1 blocking antibodies to induce sustained remissions in some patients argues that some tumors may already exist in this optimal state. The ideal goal then is to induce a shift in the tumor microenvironment toward this optimal state for tumors that would otherwise be minimally or unresponsive to T cell immunotherapy. One approach to describing this state would be to perform molecular profiling of the tumor microenvironment. For example, melanomas characterized by a preexisting T cellinflamed tumor microenvironment appear to display a distinct molecular profile characterized by high expression of three immunosuppressive mechanisms including IDO, PD-L1 and Foxp3 Moreover, it will also be important to understand the role of immune profiling for selecting patients who are likely to respond to immunotherapy.
Tailoring cancer immunotherapy
Strategies to enhance the efficacy of immunotherapy will need to consider immune escape mechanisms exploited by cancer. As discussed above, malignant cells can evade immune elimination through loss of antigenicity and/or loss of immunogenicity and by coordinating an immunosuppressive microenvironment. The degree to which a tumor exploits these mechanisms
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Concluding remarks
The immune system has a pivotal role in shaping tumor biology. Strategies that restore the capacity of the immune system to recognize and eliminate malignant cells have produced Step 1
Modulate tumor inflammation
Step 2
Induce/Boost T cell anti-tumor immunity
Step 3 
